Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025

Boundless Bio, Inc.

Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.
Cash and investments $152.1M as of Dec 31, 2024; projected operating runway into 2027.
BBI-355 Phase 1/2 POTENTIATE trial ongoing; initial proof-of-concept safety/activity data due H2 2025.
Novel Kinesin program: development candidate nomination targeted for mid-2025, IND submission H1 2026.
Appointed Dr. Robert Doebele as Chief Medical Officer in February 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.